Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
H
145020
vs
K
KOSPI 200
Over the past 12 months, Hugel Inc has underperformed KOSPI 200, delivering a return of -35% compared to KOSPI 200's +119% growth.
Stocks Performance
145020 vs KOSPI 200
Performance Gap
145020 vs KOSPI 200
Performance By Year
145020 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hugel Inc
Glance View
Hugel Inc. is a South Korean medical aesthetics company that develops and sells products used in cosmetic treatments. Its core products include botulinum toxin injectables, dermal fillers, and related skin-care and medical aesthetic products. These are used by doctors and clinics to reduce wrinkles, add facial volume, and improve appearance without surgery. The company sells mainly to hospitals, dermatology clinics, plastic surgery clinics, and distributors that serve those treatment centers. It makes money by manufacturing these products and selling them through domestic and overseas channels, often through local partners who handle sales and distribution in each market. That means Hugel sits in the value chain as a product maker for professional aesthetic use, not as a clinic or consumer brand alone. What makes Hugel’s business model different is that it depends on repeat use in cosmetic medicine and on the rules and approvals that govern injectable medical products. Its products are bought by trained professionals, so demand is tied to clinic procedures rather than everyday retail shopping. This gives the company a focused role in the aesthetics market, with revenue driven by product sales into a specialized medical channel.